期刊
ANTIVIRAL RESEARCH
卷 137, 期 -, 页码 41-48出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2016.10.015
关键词
HTLV-1; Vaccine; Oncogene; Retrovirus; Leukemia
资金
- Fonds National de la Recherche Scientifique (FNRS)
- Televie
- Interuniversity Attraction Poles (IAP) Program Virus-host interplay at the early phases of infection BELVIR
- Belgian Science Policy Office
- Belgian Foundation against Cancer (FBC)
- Centre anticancereux pres ULg (CAC)
- Fonds Leon Fredericq (FLF)
- AgricultureIsLife project of Gembloux Agrobiotech (GxABT)
- ULg Fonds Speciaux pour la Recherche
- Plan Cancer of the Service Public Federal
- Grants-in-Aid for Scientific Research [16H05248] Funding Source: KAKEN
Even though an estimated 10-20 million people worldwide are infected with the oncogenic retrovirus, human T-Iymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据